# Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

> **NCT05676073** · PHASE2 · COMPLETED · sponsor: **Shenzhen Kexing Pharmaceutical Co., Ltd.** · enrollment: 91 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SHEN26 dose 1
- **DRUG:** SHEN26 dose 2
- **DRUG:** SHEN26 placebo

## Key facts

- **NCT ID:** NCT05676073
- **Lead sponsor:** Shenzhen Kexing Pharmaceutical Co., Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-08
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-01-27
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676073, "Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05676073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*